Relationship between calculated carboplatin area under the curve, using the Cockcroft-Calvert formula and the Chatelut formula, and thrombocytopenia induced by intraperitoneal carboplatin in combination with intravenous cyclophosphamide

被引：1

作者：

Fujiwara K. ^{[1
]}

Yamauchi H. ^{[1
]}

Yoshida T. ^{[1
]}

Kohn I. ^{[1
]}

机构：

[1] Department of Obstetrics, Kawasaki Medical School, Kurashiki 701-0192

来源：

International Journal of Clinical Oncology | 1998年 / 3卷 / 5期

关键词：

Carboplatin; Chatelut formula; Cockcroft- Calvert formula; Cyclophosphamide; Intraperitoneal administration;

D O I：

10.1007/BF02628051

中图分类号：

学科分类号：

摘要：

Background. There is no standard formula to estimate doses for the intraperitoneal (IP) administration of carboplatin. We evaluated a combination of the Cockcroft and the Calvert (Cockcroft-Calvert) formula to determine the area under the curve (AUC) for IP carboplatin co-administered with intravenous (IV) cyclophosphamide (CPM). We also evaluated the correlation of carboplatin clearance determined by the Chatelut formula with carboplatin clearance determined by the Cockcroft-Calvert formula. Methods. We performed a retrospective study of the records of 149 treatments in 30 patients who received IP carboplatin and IV CPM for ovarian carcinoma. The glomerular filtration rate was calculated with the Cockcroft formula. Carboplatin doses were determined based on the body surface area. The Cockcroft-Calvert formula was used to calculate the AUC. The Chatelut formula was also used to calculate the clearance of carboplatin and the AUC. Results. The AUC calculated with the Cockcroft-Calvert formula was well correlated to the AUC calculated with the Chatelut formula (r2 = 0.965). During the first four courses of IP carboplatin combined with IV CPM (300-500 mg/m2), the correlation between the percent decrease in platelet count and the calculated carboplatin AUC varied among methods: Cockcroft-Calvert formula AUC: r2 = 0.460; Chatelut formula AUC: r2 = 0.431; body surface area dose: r2 = 0.204; total dose: r2 = 0.143. Conclusion. To decrease patient platelet count by 67%, the optimal target AUC following IP administration of carboplatin in combination with 300-500 mg CPM/m2 IV was calculated as 6.5, using the Cockcroft-Calvert formula, and as 7.5, using the Chatelut formula. Considerable modification of the IP carboplatin dose is required after the fourth course. A prospective study is ongoing to confirm these results.

引用

页码：304 / 310

页数：6

共 17 条

[11]

Chatelut E., Canal P., Brunner V., Et al., Prediction of carboplatin clearance from standard morphological and biological patient characteristics, J Natl Cancer Inst, 87, pp. 573-580, (1995)

[12]

Cockcroft D.W., Gault M.H., Prediction of creatinine clearance from serum creatinine, Nephron, 16, pp. 31-41, (1976)

[13]

Rhodes P.J., Rhodes R.S., McClelland G.H., Et al., Evaluation of eight methods for estimating creatinine clearance in men, Clin Pharm, 6, pp. 399-406, (1987)

[14]

Egorin M.J., Van Echo D.A., Olman E.A., Et al., Prospective validation of a pharmacologically based dosing scheme for the cis- Diamminedichloroplatinum (II) analogue diamminecyclobutane-dicarboxylato-platinum, Cancer Res, 45, pp. 6502-6506, (1985)

[15]

Taguchi J., Saijo N., Miura K., Et al., Prediction of hematologic toxicity of carboplatin by creatinine clearance rate, Jpn J Cancer Res, 78, pp. 977-982, (1987)

[16]

Calvert A.H., Newell D.R., Carboplatin Pharmacokinetics/clinical Dosing, (1993)

[17]

Alberts D.S., Liu P.Y., Hannigan E.V., Et al., Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer, N Engl J Med, 335, pp. 1950-1955, (1996)

← 1 2 →